The beneficial effects of metformin and DPP-4 inhibitors suggest that patients who are established on these antidiabetic agents should remain on their current treatment (i.e., not changed to insulin) if hospitalized for COVID-19. The gene discussed is DPP4; the disease is COVID-19.